William Hrushesky to Risk Assessment
This is a "connection" page, showing publications William Hrushesky has written about Risk Assessment.
Connection Strength
0.210
-
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):852-7.
Score: 0.044
-
Re: Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004 Jun 02; 96(11):888-9.
Score: 0.036
-
Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther. 2003 Jun; 2(2):105-11.
Score: 0.034
-
Breast cancer screening: controversies and future directions. Curr Opin Obstet Gynecol. 2003 Feb; 15(1):1-8.
Score: 0.033
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.028
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.020
-
Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer. 2010 Nov 30; 10:656.
Score: 0.014